UNIGENE LABORATORIES | 0,173 Euro | 0,000 0 % | |
| WKN: 875852 ISIN: US9047531002 Ticker-Symbol: UUL | Stuttgart | 25.05.12 | 19:56 Uhr |
Branche BiotechnologieAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten | Leser | Medien | |
|---|---|---|---|---|
| 22.05. | Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies | 7 | PR Newswire | |
| BOONTON, N.J., May 22, 2012 /PRNewswire/ --Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufacture and development of peptide-based therapeutics today reported positive... Mehr lesen zu: Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies | ||||
| 21.05. | Unigene to Present at TIDES 2012 | 26 | PR Newswire | |
| BOONTON, N.J., May 21, 2012 /PRNewswire/ --Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced the... Mehr lesen zu: Unigene to Present at TIDES 2012 | ||||
| 10.05. | UNIGENE LABORATORIES INC - 10-Q, Quarterly Report | 4 | SEC Filings | |
| 07.05. | Unigene Announces First Quarter 2012 Financial Results | 38 | PR Newswire | |
| BOONTON, N.J., May 7, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), today announced financial results for the first quarter ended March 31, 2012.
First Quarter 2012 Financial Summary
Unigene... Mehr lesen zu: Unigene Announces First Quarter 2012 Financial Results | ||||
| 30.04. | UNIGENE LABORATORIES INC - 10-K/A, Annual Report | 5 | SEC Filings | |
| 03.04. | Unigene's Proprietary Oral Peptide Delivery Platform is Further Validated with Cara Therapeutics' Successful Completion of its Phase 1 Study Using Unigene's Oral Formulation of Novel Kappa Opioid Receptor Agonist, CR845 | 39 | PR Newswire | |
| BOONTON, N.J., April 3, 2012 /PRNewswire/ --Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics today announced Cara... Mehr lesen zu: Unigene's Proprietary Oral Peptide Delivery Platform is Further Validated with Cara Therapeutics' Successful Completion of its Phase 1 Study Using Unigene's Oral Formulation of Novel Kappa Opioid Receptor Agonist, CR845 | ||||
| 02.04. | Unigene Appoints Jack Wyszomierski to its Board of Directors | 11 | PR Newswire | |
| BOONTON, N.J., April 2, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics today announced the... Mehr lesen zu: Unigene Appoints Jack Wyszomierski to its Board of Directors | ||||
| 29.03. | Unigene to Present at the 11th Annual Needham Healthcare Conference | 9 | PR Newswire | |
| BOONTON, N.J., March 29, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced today... Mehr lesen zu: Unigene to Present at the 11th Annual Needham Healthcare Conference | ||||
| 15.03. | Unigene Appoints David Moskowitz as Chief Financial Officer | 43 | PR Newswire | |
| BOONTON, N.J., March 15, 2012 /PRNewswire/ --Unigene Laboratories, Inc. (OTCBB: UGNE), today announced the appointment of David Moskowitz, RPh, MBA, to the position of Chief Financial Officer.In this... Mehr lesen zu: Unigene Appoints David Moskowitz as Chief Financial Officer | ||||
| 08.03. | Unigene Announces Fourth Quarter and Full-Year 2011 Results | 38 | PR Newswire | |
| BOONTON, N.J., March 8, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), today announced financial results for the fourth quarter and full-year ended December 31, 2011. The Company highlighted... Mehr lesen zu: Unigene Announces Fourth Quarter and Full-Year 2011 Results | ||||
| 05.03. | Unigene's Proprietary Peptelligence' Platform Selected by Stealth Peptides for an Oral Phase 1 Clinical Study | 11 | PR Newswire | |
| BOONTON, N.J., March 5, 2012 /PRNewswire/ --Unigene Laboratories, Inc. (OTCBB: UGNE), today announced that the Company signed a Clinical Manufacturing Services Agreement with Stealth Peptides Inc.... Mehr lesen zu: Unigene's Proprietary Peptelligence' Platform Selected by Stealth Peptides for an Oral Phase 1 Clinical Study | ||||
| 01.03. | Unigene to Announce Fourth Quarter and Full-Year 2011 Financial Results on March 8, 2012 | 21 | PR Newswire | |
| BOONTON, N.J., March 1, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that... Mehr lesen zu: Unigene to Announce Fourth Quarter and Full-Year 2011 Financial Results on March 8, 2012 | ||||
| 27.02. | Unigene to Present at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference | 7 | PR Newswire | |
| BOONTON, N.J., Feb.27, 2012 /PRNewswire/ --Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced the... Mehr lesen zu: Unigene to Present at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference | ||||
| 08.02. | Unigene Announces Key Appointments as Biotechnologies Strategic Business Unit Continues to Grow in 2012 | 25 | PR Newswire | |
| BOONTON, N.J., Feb. 8, 2012 /PRNewswire/ --Unigene Laboratories, Inc. (OTCBB: UGNE), today announced the expansion of its Biotechnologies strategic business unit (SBU) with the promotion of Gregory... Mehr lesen zu: Unigene Announces Key Appointments as Biotechnologies Strategic Business Unit Continues to Grow in 2012 | ||||
| 07.02. | Unigene to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012 | 26 | PR Newswire | |
| BOONTON, N.J., Feb. 7, 2012 /PRNewswire/ --Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced... Mehr lesen zu: Unigene to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012 | ||||
| 01.02. | Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award | 30 | PR Newswire | |
| BOONTON, N.J., Feb. 1, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today announced that it has received the 2012 Drug Delivery Partnerships' ("DDP") Innovation... Mehr lesen zu: Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award | ||||
| 11.01. | Unigene Laboratories Granted US Patent for Peptide-Based Technology for Treatment of Obesity | 23 | PR Newswire | |
| BOONTON, N.J., Jan. 11, 2012 /PRNewswire/ --Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that... Mehr lesen zu: Unigene Laboratories Granted US Patent for Peptide-Based Technology for Treatment of Obesity | ||||
| 09.01. | Unigene Provides 2012 Business Outlook | 22 | PR Newswire | |
| BOONTON, N.J., Jan. 9, 2012 /PRNewswire/ --Unigene Laboratories, Inc. (OTCBB: UGNE) today provided a business outlook for 2012 and highlighted multiple near-term catalysts that... Mehr lesen zu: Unigene Provides 2012 Business Outlook | ||||
| 04.01. | Unigene to Present at Biotech Showcase' 2012 in San Francisco on January 9 | 8 | PR Newswire | |
| BOONTON, N.J., Jan. 4, 2012 /PRNewswire/ --Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that Ashleigh... Mehr lesen zu: Unigene to Present at Biotech Showcase' 2012 in San Francisco on January 9 | ||||
| 19.12. | Unigene's 2011 Year in Review - Key Elements in Place to Address Debt in 2012 | 32 | PR Newswire | |
| BOONTON, N.J., Dec. 19, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today highlighted its significant accomplishments in 2011 and announced that its management... Mehr lesen zu: Unigene's 2011 Year in Review - Key Elements in Place to Address Debt in 2012 | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| MEDIGENE AG | 1,211 | -1,30 % | Medigene: Wie weit geht die Rallye? |
| TALON THERAPEUTICS INC | 0,543 | +0,74 % | FDA Panel Votes 7-4 Benefits of Talon Therapeutics' (TLON) Marqibo Outweigh Risks |
| MOLOGEN AG | 10,700 | +0,56 % | Independent Research hebt Ziel für Mologen auf 21,50 Euro - 'Kaufen' |
| YM BIOSCIENCES | 1,720 | +10,82 % | YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012 |
| AMGEN INC | 55,04 | +0,51 % | Amgen Announces Voting Results Of Stockholders Meeting; CEO Kevin Sharer Retires |
Startseite • Nachrichten • Aktienkurse • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Chartanalysen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage
